Overview: Acylcarnitine C4 TestIntroduction: The Acylcarnitine C4 Test checks for Isobutyryl-CoA Dehydrogenase Deficiency, a condition that can lead to metabolic crises, heart problems, or developmental issues due to improper fat metabolism, helping guide treatment. With a rare incidence of 1 in 100,000, early detection is challenging but critical to prevent cardiomyopathy in infants, especially during fasting or illness. Following 2023 ACMG guidelines, it uses tandem mass spectrometry (MS/MS) for high specificity, supporting metabolic screening. This test is essential for diagnosis, treatment planning, and improving outcomes in biochemistry, particularly in pediatric cardiology.
Other Names: C4 Assay, Butyrylcarnitine Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for precision.
Historical Milestone: Acylcarnitine testing began in the 1990s with metabolic research by Piero Rinaldo, focusing on fatty acid oxidation defects. Tandem MS advancements in the 2000s by Thermo Fisher enhanced detection of C4 carnitine, surpassing earlier liquid chromatography-mass spectrometry (LC-MS) methods that lacked sensitivity for rare disorders.
Purpose: Measures C4 acylcarnitine levels to diagnose Isobutyryl-CoA Dehydrogenase Deficiency, guides dietary management with low-fat diets and carnitine supplementation, and evaluates patients with metabolic crises or heart issues, aiming to prevent sudden cardiac events or developmental delays.
Test Parameters: C4 acylcarnitine levels
Pretest Condition: Fasting preferred for 6-8 hours to assess baseline metabolism and detect abnormalities. Collect dried blood spot, plasma, or serum. Report history of metabolic issues, heart problems, or recent illness.
Specimen: Dried Blood Spot (filter paper, 3-5 spots), Plasma (NaHep, 2-4 mL), Serum (SST, 2-5 mL); 2 mL plasma in Na Heparin tube or dried blood spot on filter paper. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document metabolic crises, heart issues, or developmental delays. Include dietary habits, exercise patterns, or family history of metabolic disorders, noting any recent fasting or viral exposure.
Consent: Written consent required, detailing the test's purpose, deficiency risks (e.g., cardiomyopathy, sudden death), and potential risks of sample collection, emphasizing neonatal screening benefits and cardiac monitoring.
Procedural Considerations: Uses tandem mass spectrometry (MS/MS) to measure C4 levels, requiring laboratories with Thermo TSQ Quantiva systems and trained technicians to handle dried blood spots. Results are available in 2-3 days, supporting pediatric care. Performed in labs with sample drying protocols and humidity control to prevent degradation and ensure accurate metabolite detection.
Factors Affecting Result Accuracy: Improper drying, contamination with skin oils, or exposure to heat can affect results. Fasting status, medications, or concurrent illness may alter levels, necessitating controlled conditions and clinical correlation to avoid misdiagnosis.
Clinical Significance: Elevated C4 confirms Isobutyryl-CoA Dehydrogenase Deficiency, guiding carnitine supplementation and low-fat therapy to support cardiac function. Early treatment might prevent heart failure or developmental delays, while untreated cases can lead to fatal arrhythmias or sudden death. Normal levels may require genetic testing (e.g., ACAD8) to rule out carriers or alternative diagnoses.
Specialist Consultation: Consult a metabolic specialist or cardiologist for result interpretation and management, particularly for infants or those with family history, where cardiac monitoring and dietary adjustments are critical to prevent crises.
Additional Supporting Tests: Urine organic acids, ACAD8 gene analysis, or echocardiogram to confirm diagnosis and assess cardiac function, aiding in personalized care and long-term monitoring.
Test Limitations: Non-specific for severity; clinical correlation with symptoms and genetics is needed. Sensitivity varies with age and fasting state, requiring repeat testing during symptomatic periods.
References: ACMG Guidelines, 2023; Journal of Pediatrics, Andresen BS, 2022.
